Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Radiation Oncology
Published in: Journal of Radiation Oncology 2/2019

01-06-2019 | Rectal Cancer | Original Research

Neoadjuvant chemotherapy and high-dose radiation using intensity-modulated radiotherapy followed by rectal sparing TEM for distal rectal cancer

Authors: Kinjal Parikh, Albert S DeNittis, Gerald Marks, Erik Zeger, David Cho, John Marks

Published in: Journal of Radiation Oncology | Issue 2/2019

Login to get access

Abstract

Purpose

For distal rectal tumors, abdominoperineal resection may achieve local control but with significant morbidity. High-dose radiation can improve pathologic response and allow for full-thickness local excision (FTLE) with comparable outcomes and improved morbidity. We report 15 years of data on distal rectal cancer treated with chemotherapy, intensity-modulated radiotherapy (IMRT), and FTLE via transanal endoscopic microsurgery.

Methods and materials

Forty-four patients were treated for cT1–T3, N0, and M0 distal rectal cancer using IMRT at 5580 cGy with 5-FU chemotherapy, followed by FTLE. Local recurrence (LR), disease-free survival (DFS), and overall survival (OS) were reported.

Results

Median follow-up was 51 months. Three patients (6.8%) had LR, all salvaged surgically. Mean DFS and OS are 8.56 and 9.10 years, respectively. DFS and OS were strongly associated with pathologic response to chemoradiotherapy (p = 0.043 and p = 0.023, respectively). Thirty-four patients (77%) are alive with no disease. Postoperative grade I–II complications noted in 17 patients and grade III complications in 2 patients. No patients required a diverting colostomy.

Conclusions

High-dose IMRT and chemotherapy followed by FTLE to treat distal rectal cancers are well tolerated and effective. FTLE may improve outcomes and minimize complications in appropriately selected patients. Randomized clinical trials are needed to compare it with standard surgery.
Literature
1.
Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois É, Maurel J, Seitz JF (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24(28):4620–4625CrossRefPubMed
2.
Hofheinz R, Wenz F, Post S, Matzdorff A, Laechelt S, Mueller L, Link H, Moehler M, Burkholder I, Hochhaus A (2009) Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo-) adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): safety results of a randomized, phase III trial. J Clin Oncol 27(15S):4014
3.
4.
Guerrieri M, Gesuita R, Ghiselli R, Lezoche G, Budassi A, Baldarelli M (2014) Treatment of rectal cancer by transanal endoscopic microsurgery: experience with 425 patients. World J Gastroenterol: WJG 20(28):9556–9563CrossRefPubMedPubMedCentral
5.
6.
Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, Rutten H, Pahlman L, Glimelius B, Leer JW, van de Velde CJ (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246(5):693–701CrossRefPubMed
7.
Maggiori L, Panis Y (2012) Transanal endoscopic microsurgery (TEM) for T1 rectal cancer. Acta chirurgica Iugoslavica 59(2):87–90CrossRefPubMed
8.
Veereman G, Vlayen J, Robays J, Fairon N, Stordeur S, Rolfo C, Bielen D, Bols A, Demetter P, D’hoore A, Haustermans K (2017) Systematic review and meta-analysis of local resection or transanal endoscopic microsurgery versus radical resection in stage i rectal cancer: a real standard? Crit Rev Oncol Hematol 114:43–52CrossRefPubMed
9.
Lu JY, Lin GL, Qiu HZ, Xiao Y, Wu B, Zhou JL (2015) Comparison of transanal endoscopic microsurgery and total mesorectal excision in the treatment of T1 rectal cancer: a meta-analysis. PLoS One 10(10):e0141427CrossRefPubMedPubMedCentral
10.
Allaix ME, Arezzo A, Giraudo G, Morino M (2012) Transanal endoscopic microsurgery vs. laparoscopic total mesorectal excision for T2N0 rectal cancer. J Gastrointest Surg 16(12):2280–2287CrossRefPubMed
11.
Bujko K, Richter P, Smith FM, Polkowski W, Szczepkowski M, Rutkowski A, Dziki A, Pietrzak L, Kołodziejczyk M, Kuśnierz J, Gach T (2013) Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders: a prospective multicentre study. Radiother Oncol 106(2):198–205CrossRefPubMed
12.
Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23(34):8688–8696CrossRefPubMed
13.
Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY (2012) Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 30(15):1770–1776CrossRefPubMedPubMedCentral
14.
Habr-Gama A, Gama-Rodrigues J, São Julião GP, Proscurshim I, Sabbagh C, Lynn PB, Perez RO (2014) Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 88(4):822–828CrossRefPubMed
15.
Wiltshire KL, Ward IG, Swallow C, Oza AM, Cummings B, Pond GR, Catton P, Kim J, Ringash J, Wong CS, Wong R (2006) Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. Int J Radiat Oncol Biol Phys 64(3):709–716CrossRefPubMed
16.
17.
Gunther JR, Chadha AS, Shin US, Park IJ, Kattepogu KV, Grant JD, Weksberg DC, Eng C, Kopetz SE, Das P, Delclos ME (2017) Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: a matched-pair analysis. Adv Radiat Oncol
18.
Verseveld M, De Graaf EJ, Verhoef C, van Meerten E, Punt CJ, de Hingh IH, Nagtegaal ID, Nuyttens JJ, Marijnen CA, de Wilt JH (2015) Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg 102(7):853–860CrossRefPubMed
19.
Issa N, Murninkas A, Schmilovitz-Weiss H, Agbarya A, Powsner E (2015) Transanal endoscopic microsurgery after neoadjuvant chemoradiotherapy for rectal cancer. J Laparoendosc Adv Surg Tech 25(8):617–624CrossRef
20.
Mohiuddin M, Paulus R, Mitchell E, Hanna N, Yuen A, Nichols R, Yalavarthi S, Hayostek C, Willett C (2013) Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. Int J Radiat Oncol Biol Phys 86(3):523–528CrossRefPubMedPubMedCentral
21.
Samuelian JM, Callister MD, Ashman JB, Young-Fadok TM, Borad MJ, Gunderson LL (2012) Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 82(5):1981–1987CrossRefPubMed
22.
Wang JF, Li H, Xiong H, Huang H, Zou YM (2016) Influence of position and radiation technique on organs at risk in radiotherapy of rectal cancer. J Huazhong Univ Sci Technolog Med Sci 36(5):741–746CrossRefPubMed
23.
Zhao J, Hu W, Cai G, Wang J, Xie J, Peng J, Zhang Z (2016) Dosimetric comparisons of VMAT, IMRT and 3DCRT for locally advanced rectal cancer with simultaneous integrated boost. Oncotarget 7(5):6345–6351PubMed
24.
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213CrossRefPubMedPubMedCentral
25.
Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A, Collette L (2005) Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. J Clin Oncol 23(24):5620–5627CrossRefPubMed
26.
Winde G, Nottberg H, Keller R, Schmid KW, Bünte H (1996) Surgical cure for early rectal carcinomas (T1). Dis Colon Rectum 39(9):969–976CrossRefPubMed
27.
Lee W, Lee D, Choi S, Chun H (2003) Transanal endoscopic microsurgery and radical surgery for T1 and T2 rectal cancer. Surg Endosc 17(8):1283–1287CrossRefPubMed
28.
29.
Wong SJ, Winter K, Meropol NJ, Anne R, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Willett CG (2008) RTOG 0247: a randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. J Clin Oncol 26(15_suppl):4021CrossRef
30.
Guerrero Urbano MT, Henrys AJ, Adams EJ, Norman AR, Bedford JL, Harrington KJ, Nutting CM, Dearnaley DP, Tait DM (2006) Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys 65(3):907–916CrossRefPubMed
Metadata
Title
Neoadjuvant chemotherapy and high-dose radiation using intensity-modulated radiotherapy followed by rectal sparing TEM for distal rectal cancer
Authors
Kinjal Parikh
Albert S DeNittis
Gerald Marks
Erik Zeger
David Cho
John Marks
Publication date
01-06-2019
Publisher
Springer Berlin Heidelberg
Published in
Journal of Radiation Oncology / Issue 2/2019
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-019-00389-9

Other articles of this Issue 2/2019

Journal of Radiation Oncology 2/2019 Go to the issue

Abstracts

THE PROCEEDINGS OF THE RADIATION ONCOLOGY SUMMIT: ACRO 2019

Original Research

Changes in prostate-specific antigen midway through salvage radiotherapy may be associated with long-term outcomes

Original Research

A risk model for lung complication combining radiation therapy and chronic obstructive pulmonary disease

Original Research

Quantitative assessment of the efficacy of two different treatment plan optimization algorithms in treating tumors in locations of high heterogeneity

Correction

Correction to: Stereotactic body radiation therapy for non-small cell lung cancer patients with prior history of thoracic surgery and/or radiation therapy: the influence of smoking, size, and central location on risk of complications

Original Research

Fast in situ image reconstruction for proton radiography
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits